Identifying And Prioritising Points For Intervention To Reduce Cardiovascular Disease Inequalities In Australia
Funder
National Health and Medical Research Council
Funding Amount
$550,669.00
Summary
This project investigates inequalities in cardiovascular disease risk, incidence, healthcare and outcomes, focussing on socio-economic status, rurality, mental health and Aboriginality. It will work with partner organisations and use a range of data sources - including representative population data, clinical datasets, large scale linked data and qualitative data - to better understand variation in cardiovascular disease, to reduce inequalities and improve outcomes.
Identifying Levels And Types Of Emotion That Maximise Effectiveness Of Anti-smoking Ads, Especially In Low SES Smokers
Funder
National Health and Medical Research Council
Funding Amount
$371,552.00
Summary
Seizing the rare opportunity presented by well funded anti-tobacco media campaigns in Victoria over 2011-13, this research aims to investigate the optimum strength and type of emotion evoked by anti-smoking ads by examining smokers responses to a variety of ads. To decide whether campaign messages need to be tailored for disadvantaged groups, this research focuses on whether the impact of emotion in anti-smoking ads is different in disadvantaged smokers as compared to the broader population.
Health Related Quality Of Life After Critical Illness In Adults
Funder
National Health and Medical Research Council
Funding Amount
$105,842.00
Summary
The aim of this study is to determine the health related quality of life (HRQoL) of patients after critical illness. There is currently a paucity of evidence about the long-term HRQoL outcomes of critically ill patients in Australia. The ‘value-added’ aspects of this study are that it is a large multi-centre, Australian study, using a well-validated instrument examining HRQoL in regard to local context, enabling comparison with international studies.
Novel Genes And Protein In Non-alcoholic Fatty Liver Disease: Potential Basis Of A Serum-based Assessment Of Disease Sta
Funder
National Health and Medical Research Council
Funding Amount
$200,000.00
Summary
The most common cause of elevated liver function tests is non-alcoholic fatty liver disease (NAFLD). NALFD is a spectrum of disease ranging from steatosis, to non-alcoholic steatohepatitis (NASH), a condition associated with the development of fibrosis in the majority of individuals. Approximately 20% and 3% of adults are affected with NAFLD and NASH, respectively, and NAFLD is expected to become the next major liver epidemic facing the western world, far exceeding the prevalence of chronic infe ....The most common cause of elevated liver function tests is non-alcoholic fatty liver disease (NAFLD). NALFD is a spectrum of disease ranging from steatosis, to non-alcoholic steatohepatitis (NASH), a condition associated with the development of fibrosis in the majority of individuals. Approximately 20% and 3% of adults are affected with NAFLD and NASH, respectively, and NAFLD is expected to become the next major liver epidemic facing the western world, far exceeding the prevalence of chronic infection with the hepatitis C virus. We obtained liver biopsies from patients with NAFLD, 80% of whom had NASH, and determined the expression profile analysis of each subject using 19,200 element microarrays. Our data demonstrates the concordant differential expression of 130 genes, in subjects with NAFLD that were categorizes into 6 major metabolic and regulatory pathways. Many of these genes represented uncharacterised genes. Utilising an extensive bioinformatics approach we have been able to define the genes and their protein product. The use of these proteins as a diagnostic tool for the detection of NAFLD forms the basis of a provisional patent application. However, measurements of protein levels in tissue and sera from patients with NAFLD are needed for the development of a diagnostic method. Such information would also provide significant insight into the pathogenesis of NAFLD. The AIMS are: 1) Production of antibodies against proteins encoded by candidate genes Expression profile of candidate genes 3) Expression of proteins encoded by candidate genes in patients with NAFLDRead moreRead less
The Role Of Allostatic Load As A Mediator Between Chronic Stress And Poor Health For Dementia Caregivers
Funder
National Health and Medical Research Council
Funding Amount
$237,321.00
Summary
The potential risk to caregivers of dementia patients of poor health outcomes is well documented. The burden imposed by caregiving is most often described in terms of chronic stress. While it is apparent that some stress-relieving social interventions (e.g. respite) may have short-term benefits, it is also clear that many caregivers are unable or unwilling to avail themselves of such programs. The way in which chronic stress leads to poor health is not well understood. Our study of spouse caregi ....The potential risk to caregivers of dementia patients of poor health outcomes is well documented. The burden imposed by caregiving is most often described in terms of chronic stress. While it is apparent that some stress-relieving social interventions (e.g. respite) may have short-term benefits, it is also clear that many caregivers are unable or unwilling to avail themselves of such programs. The way in which chronic stress leads to poor health is not well understood. Our study of spouse caregivers seeks to identify the groups of physiological systems that suffer cumulative wear and tear as a result of chronic stress. This wear and tear is called allostatic load, and is thought to lead to poor health. It is expected that caregivers in our study will have greater allostatic load than people who are not caregivers. Should this be the case, our results will provide the basis for the design of tailored interventions to maintain caregivers in good health. The potential of such preventive health measures is to reduce caregivers' health care costs and reliance on community support, and to help caregivers to continue providing care for their spouses at home.Read moreRead less
Gabapentin In The Treatment Of Idiopathic Chronic Cough: A Randomised Double-blind Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$331,229.00
Summary
Better treatment approaches are needed to address the significant quality of life impairment associated with chronic cough. We propose to conduct a double-blind, placebo controlled study comparing the efficacy (and safety) of oral gabapentin therapy on cough reflex severity and cough-specific quality of life in people with idiopathic cough. The advantages are a strong design, use of objective assessment techniques, and investigation of a new treatment modality for cough.